Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously.
Druker BJ, Talpaz M., Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukaemia. N Engl J Med2001; 344: 1031-1037.
2.
Dematteo RP, Ballman KV, Antonescu CR, et al. On behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet2009; 373: 1097-1104.
3.
Mathew T., Chandrashekar L., Pulimood S., et al. Imatinib-induced erythroderma. Letter to the Editor. Australas J Dermatol2007; 48: 193-194.
4.
Lacouture ME , Reilly LM, Gerami P., et al. Hand foot skin reaction in cancer patients treated with the multi-kinase inhibitors sorafenib and sunitinib . Ann Oncol2008; 19: 1955-1961.
5.
Rosenbaum SE , Wu S., Newman MA, et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer2008; 16: 557-566.
6.
Sattler M. and Griffin JDMolecular mechanism of transformation by the bcr-abl oncogene. Semin Hematol2003; 40: 4-10.
7.
Valeyrie L., Bastuji-Garin S., Revuz J., et al. Adverse reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective Letters to Editor study of 54 patients. J Am Acad Dermatol2003; 48: 201-206.
8.
Brouard MC, Prins C., Mach-Pascual S., et al. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology2001; 203: 57-59.
9.
Drummond A., Micallef-Eynaud P., Douglas WS, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol2003; 120: 911-913.
10.
Tsao AS, Kantarjian H., Cortes J., et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer2003; 98: 2483-2487.
11.
Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol2009; 161: 1045-1051.
12.
Mcpherson T. , Sherman V. and Turner R.Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol2009; 23: 82-83.
13.
Longley BJ and Carter ELSCF-KIT pathway in human epidermal melanocyte homeostasis. J Invest Dermatol1999; 113: 139-140.
14.
Busam KJ, Capodieci P., Motzer R., et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol2001; 144: 1169-1176.
